ST2/IL-33R Antibody - BSA Free
Novus Biologicals | Catalog # NBP2-53096
Loading...
Key Product Details
Species Reactivity
Validated:
Mouse, Rat
Cited:
Mouse, Rat
Predicted:
Human (100%). Backed by our 100% Guarantee.
Applications
Validated:
Immunohistochemistry, Western Blot
Cited:
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Format
BSA Free
Loading...
Product Specifications
Immunogen
Recombinant protein encompassing a sequence within the center region of human ST2/IL-33R. The exact sequence is proprietary.
Localization
Isoform C: Cell membrane, Isoform B: Secreted, Cell membrane; Single-pass type I membrane protein
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Theoretical MW
63 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Description
Novus Biologicals Rabbit ST2/IL-33R Antibody - BSA Free (NBP2-53096) is a polyclonal antibody validated for use in IHC and WB. Anti-ST2/IL-33R Antibody: Cited in 3 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Scientific Data Images for ST2/IL-33R Antibody - BSA Free
Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] -
Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Western Blot: ST2/IL-33R Antibody [NBP2-53096] -
Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Western Blot: ST2/IL-33R Antibody [NBP2-53096] -
Western Blot: ST2/IL-33R Antibody [NBP2-53096] - p38 beta mediates the IL-33-induced IA decrease. A, immunoblot analysis of p38 alpha & p38 beta protein abundance in DRGs. Mouse brains were used as positive controls. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. B, time course of IA changes (left) & bar graph (right) indicating the effect of 50 ng/mL IL-33 on IA in the presence of JX-401 (50 nM, n = 8 cells). The application of 50 nM JX-401 (n = 6 cells) alone had no significant effect on IA. Arabic numerals indicate the points utilized for the example current traces. C, immunoblot analysis showing that the protein expression level of p38 beta was significantly reduced in the p38 beta -siRNA-treated groups, while the expression of p38 alpha was not affected. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. D, example traces (left) & bar graph (right) demonstrating the effects of 50 ng/mL IL-33 on IA in cells treated with control siRNA (NC-siRNA, n = 9 cells) or p38 beta -siRNA (n = 11 cells). **p < 0.01 vs. control + NC-siRNA group, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Western Blot: ST2/IL-33R Antibody [NBP2-53096] -
Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] -
Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - The IL-33-induced IA decrease requires Syk. A, effects of 50 ng/mL IL-33 on protein abundance of phospho-JAK2 (p-JAK2)/total JAK2 (t-JAK2). Blots are representative of three independent experiments w/ beta -tubulin serving as a loading control. B, colabeling (white arrows) of ST2 & JAK2 & Syk in mouse DRG sections. Scale bar, 50 µm. C, time course of IA changes (left) & bar graph (right) showing that pretreatment of DRG neurons w/ AG490 (10 µM) did not affect IL-33-induced IA response (n = 8 cells). Application of 10 µM AG490 alone did not affect IA (n = 7 cells). Arabic numerals indicate points utilized for example current traces. D, effects of 50 ng/mL IL-33 on p-Syk protein abundance in presence/absence of ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) in DRG cells. Blots are representative of three independent experiments w/ beta -tubulin serving as a loading control. **p < 0.01 vs. control, unpaired t test. E-G, time course of IA changes showing that pretreating DRG neurons w/ R406/GS9973, but not KT-5720, prevented IL-33-induced IA response. Arabic numerals indicate points utilized for example current traces. H, bar graph showing effect of 50 ng/mL IL-33 on IA in cells pretreated w/ R406 (1 µM, n = 11 cells), GS9973 (10 µM, n = 8 cells), & KT-5720 (1 µM, n = 9 cells). Application of 1 µM R406 (n = 7 cells), 10 µM GS9973 (n = 6 cells)/1 µM KT-5720 (n = 7 cells) alone had no significant effect on IA. **p < 0.01 vs. control, paired t test. I, colabeling (white arrows) of ST2 & PKA in mouse DRG sections. Scale bar, 50 µm. J, bar graph demonstrating effect of 20 µM forskolin on IA in presence (n = 7 cells)/absence (n = 5 cells) of KT-5720 (1 µM). ***p < 0.001 vs. forskolin w/out KT-5720, paired t test. Image collected & cropped by CiteAb from following publication (https://pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Western Blot: ST2/IL-33R Antibody [NBP2-53096] -
Rat tissue extract (50 ug) was separated by 7.5% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] (NBP2-53096) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.Western Blot: ST2/IL-33R Antibody [NBP2-53096] -
Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] (NBP2-53096) diluted at 1:500.Western Blot: ST2/IL-33R Antibody [NBP2-53096] -
Rat tissue extract (50 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] (NBP2-53096) diluted at 1:500.Applications for ST2/IL-33R Antibody - BSA Free
Application
Recommended Usage
Immunohistochemistry
Validated for Immunohistochemistry from CiteAb
Western Blot
1:500 - 1:3000
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
0.1M Tris, 0.1M Glycine, 10% Glycerol
Format
BSA Free
Preservative
0.01% Thimerosal
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Background: ST2/IL-33R
Long Name
Interleukin 33 Receptor
Alternate Names
DER4, Fit-1, IL-1 R4, IL-1R4, IL-1RL1, IL-33 R, IL-33R, IL1R4, IL33R, Ly84, ST2L, ST2V, T1
Gene Symbol
IL1RL1
Additional ST2/IL-33R Products
Product Documents for ST2/IL-33R Antibody - BSA Free
Product Specific Notices for ST2/IL-33R Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
⚠ WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause reproductive toxicity with developmental effects. For more information go to www.P65Warnings.ca.gov.Related Research Areas
Citations for ST2/IL-33R Antibody - BSA Free
Customer Reviews for ST2/IL-33R Antibody - BSA Free
There are currently no reviews for this product. Be the first to review ST2/IL-33R Antibody - BSA Free and earn rewards!
Have you used ST2/IL-33R Antibody - BSA Free?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- Antigen Retrieval Protocol (PIER)
- Antigen Retrieval for Frozen Sections Protocol
- Appropriate Fixation of IHC/ICC Samples
- Cellular Response to Hypoxia Protocols
- Chromogenic IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Chromogenic Immunohistochemistry Staining of Frozen Tissue
- Detection & Visualization of Antibody Binding
- Fluorescent IHC Staining of Frozen Tissue Protocol
- Graphic Protocol for Heat-induced Epitope Retrieval
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Graphic Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- IHC Sample Preparation (Frozen sections vs Paraffin)
- Immunofluorescent IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Immunohistochemistry (IHC) and Immunocytochemistry (ICC) Protocols
- Immunohistochemistry Frozen Troubleshooting
- Immunohistochemistry Paraffin Troubleshooting
- Preparing Samples for IHC/ICC Experiments
- Preventing Non-Specific Staining (Non-Specific Binding)
- Primary Antibody Selection & Optimization
- Protocol for Heat-Induced Epitope Retrieval (HIER)
- Protocol for Making a 4% Formaldehyde Solution in PBS
- Protocol for VisUCyte™ HRP Polymer Detection Reagent
- Protocol for the Preparation & Fixation of Cells on Coverslips
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections - Graphic
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections - Graphic
- Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- R&D Systems Quality Control Western Blot Protocol
- TUNEL and Active Caspase-3 Detection by IHC/ICC Protocol
- The Importance of IHC/ICC Controls
- Troubleshooting Guide: Immunohistochemistry
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars
Loading...